Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria

 Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria

Alnylam Reports Results of Givosiran in P-III ENVISION Study to Treat Acute Hepatic Porphyria

Shots:

  • The P-III ENVISION study involves assessing of Givosiran vs PBO in patients with acute hepatic porphyria (AHP)
  • ENVISION study results:74% mean reduction of annualized rate of porphyria attacks; 90% median reduction in composite annualized attack rate (AAR); overall safety and tolerability; AEs (89.6% vs 80.4%); attack free (50% vs 16.3%); @3/6mos. 91%/83% in urinary ALA; @6mos. 73% in urinary levels of PBG; 77% in no. of annualized days on hemin; 73% in composite AAR for patients with any AHP   
  • Givosiran is an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) with its expected NDA and MAA submission in mid-2019

Click here to read full press release/ article | Ref: Alnylam | Image: Investor’s Business Daily

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post